11 – 20 of 47
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
(
- Contribution to journal › Article
- 2017
-
Mark
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
(
- Contribution to journal › Article
-
Mark
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
(
- Contribution to journal › Article
- 2016
-
Mark
Selective FcγR engagement by human agonistic anti-CD40 antibodies
(
- Contribution to journal › Debate/Note/Editorial
- 2015
-
Mark
Kick-starting the cancer-immunity cycle by targeting CD40
(
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.
(
- Contribution to journal › Article
-
Mark
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
(
- Contribution to journal › Article
- 2009
-
Mark
Attovial-based antibody nanoarrays.
(
- Contribution to journal › Article
- 2008
-
Mark
Phenotypic protein profiling of different B cell sub-populations using antibody CD-microarrays
(
- Contribution to journal › Article
-
Mark
Sensitivity of HIV-1 primary isolates to human anti-CD40 antibody-mediated suppression is related to co-receptor use
(
- Contribution to journal › Article